Details of the Drug Combinations

General Information of This Drug (ID: DM3PD2C)

Drug Name

Fluoxetine DM3PD2C

Synonyms

Eufor; Floxetine; Fluoxetin; Fluoxetina; Fluoxetinum; Fluval; Fontex; Portal; Pulvules; Reconcile; Reneuron; Fluoxetina [Spanish]; Fluoxetine Hcl; Prozac Weekly; Animex-On; Fluoxetina [INN-Spanish]; Fluoxetine (Prozac); Fluoxetine (TN); Fluoxetinum [INN-Latin]; Lilly-110140; Prozac (TN); Fluoxetine (USAN/INN); Fluoxetine [USAN:INN:BAN]; N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine; Methyl({3-phenyl-3-[4-(trifluoromethyl)phenoxy]propyl})amine; N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; Dl-3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine; Methyl-[3-phenyl-3-(4-trifluoromethyl-phenoxy)-propyl]-amine; N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine; N-methyl-3-phenyl-3-{[4-(trifluoromethyl)phenyl]oxy}propan-1-amine; (+-)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine; (+-)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine;(+/-)-Fluoxetine; (+/-)-N-Methyl-3-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-p-(p-trifluoromethylphenoxy)-3-phenylpropylamine; (+/-)-N-Methyl-3-phenyl-3-[(alpha,alpha,alpha-trifluoro-p-tolyl)oxy]propylamine; (+/-)-N-Methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propylamine]; (+/-)-N-Methyl-gamma-[4-(trifluoromethyl)phenoxy]benzenepropanamine; 3-(p-Trifluoromethylphenoxy)-N-methyl-3-phenylpropylamine

Indication

Disease Entry	ICD 11	Status	REF
Bipolar depression	N.A.	Approved	[1]
Bulimia nervosa	6B81	Approved	[1]
Depression	6A70-6A7Z	Approved	[2]
Intracerebral hemorrhage	N.A.	Approved	[1]
Major depressive disorder	6A70.3	Approved	[1]
Obsessive compulsive disorder	6B20	Approved	[1]
Panic disorder	6B01	Approved	[1]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 3	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of Indication(s)

Therapeutic Class

Antidepressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

10 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Citalopram + Fluoxetine	DCBOEH6	Citalopram	Depression	[4]
Edivoxetine + Fluoxetine	DC2JFQ5	Edivoxetine	Major Depressive Disorder	[5]
Eszopiclone + Fluoxetine	DCPCT7O	Eszopiclone	Sleep Initiation and Maintenance Disorders	[6]
Fluoxetine + Fingolimod	DCBH6WG	Fingolimod	Depression	[7]
Fluoxetine + Olanzapine	DCRO2OM	Olanzapine	Treatment Resistant Depression	[8]
Imipramine + Fluoxetine	DCEJ70F	Imipramine	Major Depression	[9]
Lisdexamfetamine + Fluoxetine	DCOC5SN	Lisdexamfetamine	Severe Mood Dysregulation	[10]
Atorvastatin + Fluoxetine	DC8VBYF	Atorvastatin	Depressive Disorder	[11]
Dapagliflozin + Fluoxetine	DCYP3SH	Dapagliflozin	Depressive Disorder	[11]
Ketamine + Fluoxetine	DCQPY5H	Ketamine	Bipolar Disorder	[12]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 DrugCom(s)

1 Approved Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Fluoxetine + Olanzapine	DC2QR75	Olanzapine	Depression	[13]
------------------------------------------------------------------------------------

References

1	Fluoxetine FDA Label
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 203).
3	Fluoxetine to Reduce Intubation and Death After COVID19 Infection
4	ClinicalTrials.gov (NCT00018902) Treatment of SSRI-Resistant Depression In Adolescents (TORDIA)
5	ClinicalTrials.gov (NCT01243957) A Study to Measure if There is Any Difference in How the Body Breaks Down or Inactivates Either Fluoxetine or LY2216684 When Both of These Medicines Are Given Together.
6	ClinicalTrials.gov (NCT00247624) Improving Sleep and Psychological Functioning in People With Depression and Insomnia
7	ClinicalTrials.gov (NCT01436643) Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With Depression
8	ClinicalTrials.gov (NCT01687478) A Study of Olanzapine and Fluoxetine for Treatment-resistant Depression
9	ClinicalTrials.gov (NCT00296725) Dichotic Listening as a Predictor of Medication Response in Depression
10	ClinicalTrials.gov (NCT01714310) Characterization and Sequential Pharmacotherapy of Severe Mood Dysregulation
11	ClinicalTrials.gov (NCT05792540) Clinical Study to Evaluate the Possible Efficacy of Dapagliflozin and Atorvastatin in Patients With Major Depressive Disorders
12	ClinicalTrials.gov (NCT01833897) NMDA Antagonists in Bipolar Depression
13	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015